FDA Proposes 'No Clinical Need' to Compound GLP-1 Drugs From Bulk Ingredients
The agency's proposed determination would bar outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk active ingredient, unless a new shortage intervenes.
On May 1, 2026, the Food and Drug Administration published a proposed determination that could reshape the compounded weight-loss and diabetes market: it tentatively found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk active ingredient. The notice (Docket No. FDA-2018-N-3240) proposes to leave all three GLP-1 receptor agonists off the section 503B Bulks List.
That list matters because of how federal law channels compounding. Under section 503B of the Federal Food, Drug, and Cosmetic Act, a registered outsourcing facility generally may not compound a drug from a bulk substance unless the substance appears on the 503B Bulks List, or the finished drug is on FDA’s shortage list at the time it is made. Semaglutide and tirzepatide were both on that shortage list during the supply crunch (semaglutide from 2022 to 2025, tirzepatide from 2022 to 2024) but have since come off it. With the shortage door closed, listing became the compounders’ remaining path. FDA is now proposing to close that one too.
The rationale turns on a specific reading of “clinical need.” FDA applies a threshold, two-part test: is there an attribute of the FDA-approved product that makes it medically unsuitable for some patients, and would the compounded version address that attribute; and must the drug be made from bulk rather than from an approved product? The agency wrote that it “did not answer ‘yes’ to both of the threshold questions” for any of the three substances, and so did not proceed to weigh safety or effectiveness.
Nominators, among them the Outsourcing Facilities Association and BPI Labs, had argued for sublingual, buccal, and oral routes; for “microdosing” and higher-than-approved strengths; for propylene-glycol-free injections; and for combination products mixing the peptide with pyridoxine or an antiemetic. FDA rejected each, concluding the nominations described preferences, convenience, or supply concerns rather than an attribute making the approved drugs medically unsuitable. The agency said it does not treat shortages, backorders, cost, or the convenience of a ready-to-use form as “clinical need.”
Novo Nordisk (semaglutide and liraglutide) and Eli Lilly (tirzepatide) had filed comments opposing the nominations; the branded manufacturers’ position prevailed at the proposal stage.
This is a proposal, not a final rule. FDA opened a 60-day comment window closing June 30, 2026, then, in a notice published June 26, granted a 30-day extension to July 30, 2026, after a request argued the original period was too short for “complex clinical, public health, and legal issues.” As the law firm Epstein Becker & Green noted in a May 6 analysis, liraglutide injection’s continued presence on the shortage list preserves a narrow, temporary compounding pathway for that drug alone; if the determination is finalized, compounded semaglutide and tirzepatide from bulk would be off the table absent a new shortage.
Frequently Asked Questions
What did the FDA propose on May 1, 2026, regarding compounded GLP-1 drugs?
On May 1, 2026, the FDA published a proposed determination that it found no clinical need for outsourcing facilities to compound semaglutide, tirzepatide, or liraglutide from bulk active ingredients. The proposal, published under Docket No. FDA-2018-N-3240, would leave all three GLP-1 receptor agonists off the section 503B Bulks List, which is the legal pathway that allows registered outsourcing facilities to compound drugs from bulk substances. This is currently a proposal, not a final rule. Please consult a qualified healthcare professional for questions about your specific medications or treatment options. This is not medical advice.
Why does it matter whether a drug appears on the FDA's section 503B Bulks List?
Under section 503B of the Federal Food, Drug, and Cosmetic Act, a registered outsourcing facility generally cannot compound a drug from a bulk substance unless that substance is on the 503B Bulks List or the finished drug is on FDA's drug shortage list at the time it is compounded. Semaglutide and tirzepatide were previously on the shortage list — semaglutide from 2022 to 2025 and tirzepatide from 2022 to 2024 — but both have since been removed. With the shortage pathway closed, placement on the 503B Bulks List was the remaining legal route for bulk compounding. The FDA's proposal would close that remaining pathway as well. This is not medical advice.
How does the FDA define 'clinical need' when evaluating whether a drug should be added to the 503B Bulks List?
The FDA applies a two-part threshold test to determine clinical need. First, it asks whether there is an attribute of the FDA-approved product that makes it medically unsuitable for some patients and whether the compounded version would address that attribute. Second, it asks whether the drug must be made from bulk rather than from an approved finished product. The FDA stated that it did not answer 'yes' to both threshold questions for any of the three substances — semaglutide, tirzepatide, or liraglutide — and therefore did not proceed further in its analysis. Notably, the agency stated that shortages, cost, backorders, or convenience of a ready-to-use form do not constitute 'clinical need' under this framework. This is not medical advice.
What arguments did compounding supporters make, and how did the FDA respond?
Nominators, including the Outsourcing Facilities Association and BPI Labs, argued in favor of bulk compounding on several grounds. These included alternative delivery routes such as sublingual, buccal, and oral forms; 'microdosing' and higher-than-approved strengths; propylene-glycol-free injectable formulations; and combination products mixing the peptide with pyridoxine or an antiemetic. The FDA rejected each of these arguments, concluding that the nominations described patient or prescriber preferences, convenience, or supply concerns rather than attributes that make the FDA-approved products medically unsuitable for some patients. This is not medical advice.
Is the FDA's proposed determination final, and how can the public weigh in?
No, the proposal is not a final rule. When it was published on May 1, 2026, the FDA opened a 60-day public comment period originally set to close June 30, 2026. On June 26, 2026, the FDA published a notice granting a 30-day extension to July 30, 2026, after a request argued the original period was too short to address the complex clinical, public health, and legal issues involved. Members of the public, healthcare professionals, and industry stakeholders could submit comments through the official docket during the open comment period. This is not medical advice.
This content is for informational purposes only and is not medical advice. Consult a qualified healthcare professional for any medical concerns, diagnosis, or treatment.